Thyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer
Journal Title: Asia Oceania Journal of Nuclear Medicine & Biology - Year 2013, Vol 1, Issue 1
Abstract
Article type: Original Article; Received 7 Feb 2013, Revised 6 April 2013 , Accepted 26 April 2013 * Corresponding author: Daiki Kayano, Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, 920-8641, Japan, Telephone number: +81-76-265-2333, Fax number: +81-76-234-4257, E-mail: kayano@nmd.m.kanazawa-u.ac.jp © 2013 mums.ac.ir. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. keyword: thyroid cancer, 131I, hormone, replacement Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months. Since all the patients obviously had residual lesions by their serum thyroglobulin levels or their scintigrams at the first therapies, they underwent the second 131I therapies without diagnostic scintigraphy after the first therapies. After confirming the sufficient elevation of TSH concentration, thyroid hormone replacement was resumed one day before 131I administration (3.7-7.4GBq). The ablation rate of thyroid remnant at the first 131I therapy was evaluated by comparing 131I post-therapeutic images of the two treatments. Results: Three patients were administrated thyroid hormone after 131I therapy because of insufficient TSH concentration under thyroid hormone withdrawal. In the remaining 26 patients, 41 thyroid remnant accumulations were detected in all 26 patients at the first 131I therapy. Based on the second 131I post-therapeutic images, successful ablation was confirmed in 24 of 26 patients (92.3%) and 38 of 41 sites (92.7%), which was comparable with historically reported ablation rates. Conclusion: Thyroid hormone replacement one day before 131I therapy could provide a sufficiently high ablation rate in patients with DTC.
Authors and Affiliations
Daiki Kayano, Junichi Taki, Anri Inaki, Hiroshi Wakabayashi, Ayane Nakamura, Makoto Fukuoka, Seigo Kinuya
Keywords
Related Articles
- EP ID EP125624
- DOI -
- Views 64
- Downloads 0
Clinical value and severity of myocardial perfusion defects in asymptomatic diabetic patients with negative or weakly positive exercise treadmill test
Objective: Although coronary artery disease (CAD) is the leading cause of death in type 2 diabetic patients, it is frequently asymptomatic. Myocardial perfusion imaging (MPI) is reported to show ischemia in a significan...
A big to advance scientific publication & cooperation in the breigg isotenp forward
Thyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer
Article type: Original Article; Received 7 Feb 2013, Revised 6 April 2013 , Accepted 26 April 2013 * Corresponding author: Daiki Kayano, Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, K...
History and Perspectives of AOFNMB
Treatment efficacy of 153Sm-EDTMP for painful bone metastasis
Introduction: Involvement of the skeleton can cause an excruciating pain in two-thirds of terminal patients with a history of malignancy. Due to several limitations of other therapies, such as analgesics, bisphosphonate...